Flinn Scholars News

AzBio, Utah pharma form research alliance

Summary:

A Utah-based pharmaceutical company has announced plans to collaborate on research with the Arizona Biodesign Institute at Arizona State University, according to the Business Journal.

Full Story:

A Utah-based pharmaceutical company has announced plans to collaborate on research with the Arizona Biodesign Institute at Arizona State University, according to the Business Journal.

Prolexys Pharmaceuticals Inc. will work with an institute research team on the discovery of small molecules that modulate vascular tone and are effective in the treatment of clinical conditions related to blood flow.

The institute's team, led by Colleen Brophy, Alyssa Panitch and Lokesh Joshi, has already made significant strides in area of signal transduction pathways leading to vasorelaxation.

The three researchers are currently working on a side-effect-free, smooth-muscle relaxant that they hope will increase the success rate of bypass surgeries. They have received a five-year, $700,000 grant from the National Institutes of Health in support of their research and have formed a company, AzERx Inc., to speed up development of the drug, according to the State Press.

The small molecules and peptides resulting from the collaboration could potentially be used to prevent shock associated with hypothermia and/or sepsis, or in the prevention of certain types of stroke.


For more information:

"Utah firm signs research deal with Arizona Biodesign Institute," Business Journal, 04/05/2004

"Professors develop heart surgery drug," State Press, 03/29/2004